ArticleIJU case reports2026
Secondary Colonic Adenocarcinoma After Continent Cutaneous Urinary Diversion a.m. Lundiana-An Aggressive Disease Entity With High Risk of Locally Advanced Disease and Metastases.
Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: We herein report two patients developing secondary adenocarcinomas arising in colonic segments used for urinary diversion a.m. Lundiana in a population-based series 16 and 27 years after cystectomy, respectively. Case Presentation: Following initial partial resection of the pouch, both patients experienced local recurrence; one subsequently developed distant metastases and died from secondary adenocarcinoma, whereas the other patient underwent extirpation of the pouch and re-diversion with an ileal conduit. Conclusions: Based on these patients, upfront radical surgery would have been a more effective treatment. In this patient population, clinical awareness but not screening for secondary adenocarcinomas seems to be the most appropriate strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.